Abacus Global Management, Inc.
ABXAbacus Global Management, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages while the P/BV sits at the 56th percentile of its own 1-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, with the the net margin at 16.7%. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Abacus Global Management, Inc. trades at $9.2, between stages. That is +1.1% against its own 200-day average. It sits at 61% of a 52-week range of $5 to $12. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is between stages. At $9.2 it trades +1.1% versus its 200-day average and sits at 61% of its 52-week range ($5–$12).
Against the market, two honest reads. Cumulative: over the last 1.2 years the stock moved +87% while the S&P 500 moved +21% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
Abacus Global Management, Inc. trades at 2.1× P/BV, mid-range by its own standards (56th percentile). Its long-run median P/BV is 2.0×, measured across 1.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 2.1× is mid-range by its own standards (56th percentile), against a long-run median of 2.0× measured over 1.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The honest context for that discount: a bank earning about 7% on its equity is worth less per dollar of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.
Put together: the multiple is unremarkable against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Abacus Global Management, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +118.2% | +81.7% | — | — |
| Profit | — | +10.1% | — | — |
| EPS | — | −17.0% | — | — |
| Stock price | +47.8% | — | — | — |
4-Factor Sector Score
45.8/100 — rank 9 of 17 in Insurance - Life · 61% evidence confidence
Abacus Global Management, Inc. scores 45.8 out of 100 against the 17 companies it is compared with in Insurance - Life, ranking 9. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.3 + 12.3 + 4.1 + 12.1 = 45.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
Abacus Global Management, Inc. reported $0.1 B of income in the Mar 26 quarter, +50.0% year on year. That is the 11th straight quarter of year-on-year growth. Over 3 years it has compounded at 81.7% a year. The last full year, FY25, came in at $0.2 B. The last four reported quarters add to $0.3 B.
FY25 revenue came in at $0.2 B (+118.2% on the year), capping 3 years at 81.7% compound. The latest quarter (Mar 26) printed $0.1 B, +50.0% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +95.8% growth against the decade's 81.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +92.3% over the last 4 quarters against +89.0%/yr over the last 8 — accelerating.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
Abacus Global Management, Inc.'s net margin is 16.7% in the Mar 26 quarter, −8.3 percentage points against the same quarter a year ago. Across 4 fiscal years the net margin has ranged −18.2% to 75.0%. The current quarter sits inside that band.
The latest quarter's net margin is 16.7%, −8.3 pp against the same quarter a year ago. Across 4 fiscal years the net margin has ranged −18.2%–75.0%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Abacus Global Management, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.0 B. The 3-year compound rate is 10.1%. That is 16.7% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY25 printed $0.0 B (null), and the 3-year compound rate is 10.1%.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for Abacus Global Management, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
Abacus Global Management, Inc.'s revenue grew +118.2% in FY25 to $0.2 B, so the book is growing. The latest quarter ran +50.0% year on year. The net margin on that income is 16.7%, −8.3 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY25 revenue was $0.2 B, +118.2% on the year, and the latest quarter ran +50.0% year on year. The net margin on that revenue is 16.7% this quarter (−8.3 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
Abacus Global Management, Inc. earns a return on equity of 10% in FY25. Its trough over the ladder below was −5% in FY24. On the asset side every $100 of the balance sheet earned about $7.05, which is the return before leverage is applied.
FY25 ROE came in at 10%, recovered from a FY24 trough of −5%. On assets, the latest reading is about 7.05% — every $100 the bank deploys earns roughly $7.05 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.
Why ROE moved: profit compounded 10.1% a year over 3 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Abacus Global Management, Inc. has 1 quarter of declared dividends on file — too few for a trailing-twelve-month figure. The most recent declaration was $0.20 for Dec 25.
Abacus Global Management, Inc. has declared a dividend in 1 of the last 12 reported quarters, most recently $0.20 for Dec 25. That is fewer than four quarters, so no trailing-twelve-month total is shown rather than one built from a partial year.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
10.5% of Abacus Global Management, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 8.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 10.5% of the float is sold short, and at typical trading volumes it would take about 8.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Abacus Global Management, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Globe Life Inc.GL | 64.7/100Mixed-positive evidence60% evidence | FADING | 21.9/35 Income — · PAT — 26% evidence | 18.6/25 ROA 2.1% · ROE 10.6% · GNPA — 68% evidence | 11.7/20 P/BV 1.78× · P/BV÷ROE 0.17 70% evidence | 12.5/20 RS sector 8.5% · RS bench 7.1% · 1Y 18.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 18.6 + 11.7 + 12.5 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Lincoln National CorporationLNC | 59.6/100Mixed-positive evidence60% evidence | BREAKING OUT | 19.3/35 Income — · PAT — 26% evidence | 11.6/25 ROA 0.3% · ROE 12.7% · GNPA — 68% evidence | 16.7/20 P/BV 0.6× · P/BV÷ROE 0.05 70% evidence | 12.0/20 RS sector 1.3% · RS bench -0.1% · 1Y 2.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 11.6 + 16.7 + 12 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3CNO Financial Group, Inc.CNO | 59.6/100Mixed-positive evidence60% evidence | LEADER | 19.2/35 Income — · PAT — 26% evidence | 16.5/25 ROA 1.9% · ROE 4.9% · GNPA — 68% evidence | 6.6/20 P/BV 1.84× · P/BV÷ROE 0.38 70% evidence | 17.3/20 RS sector 16.2% · RS bench 14.7% · 1Y 40.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 16.5 + 6.6 + 17.3 = 59.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4Manulife Financial CorporationMFC | 55.3/100Mixed-positive evidence80% evidence | LEADER | 21.5/35 Income 18.1% · PAT 11.8% 81% evidence | 12.7/25 ROA 1% · ROE 4.4% · GNPA — 68% evidence | 6.0/20 P/BV 1.83× · P/BV÷ROE 0.41 70% evidence | 15.1/20 RS sector 10.3% · RS bench 8.8% · 1Y 38.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 12.7 + 6 + 15.1 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Primerica, Inc.PRI | 51.7/100Mixed-positive evidence76% evidence | BREAKING OUT | 19.4/35 Income 6.4% · PAT 54.1% 71% evidence | 15.5/25 ROA 1.3% · ROE 8% · GNPA — 68% evidence | 5.7/20 P/BV 3.12× · P/BV÷ROE 0.39 70% evidence | 11.1/20 RS sector 1.4% · RS bench 0.1% · 1Y 6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 15.5 + 5.7 + 11.1 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Prudential Financial, Inc.PRU | 48.6/100Mixed-negative evidence80% evidence | BREAKING OUT | 21.9/35 Income 6.8% · PAT 100% 81% evidence | 7.7/25 ROA 0.1% · ROE 2.8% · GNPA — 68% evidence | 5.9/20 P/BV 1.19× · P/BV÷ROE 0.42 70% evidence | 13.1/20 RS sector 3.1% · RS bench 1.7% · 1Y 13%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 7.7 + 5.9 + 13.1 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aflac IncorporatedAFL | 47.4/100Mixed-negative evidence80% evidence | TURNING | 25.0/35 Income 13.6% · PAT 99.5% 81% evidence | 11.6/25 ROA 0.7% · ROE 2.9% · GNPA — 68% evidence | 4.4/20 P/BV 1.94× · P/BV÷ROE 0.67 70% evidence | 6.4/20 RS sector -2.8% · RS bench -4% · 1Y 8.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 11.6 + 4.4 + 6.4 = 47.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -2.8% and the one-year return is 8.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Unum GroupUNM | 46.3/100Mixed-negative evidence60% evidence | TURNING | 14.2/35 Income — · PAT — 26% evidence | 10.1/25 ROA 0.5% · ROE 2.3% · GNPA — 68% evidence | 5.2/20 P/BV 1.31× · P/BV÷ROE 0.57 70% evidence | 16.8/20 RS sector 11.3% · RS bench 9.9% · 1Y 24.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 10.1 + 5.2 + 16.8 = 46.3 · Decision use: Price leads the evidence: RS versus the benchmark is 9.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Abacus Global Management, Inc.this pageABX | 45.8/100Mixed-negative evidence61% evidence | ASLEEP | 17.3/35 Income 86.6% · PAT — 45% evidence | 12.3/25 ROA 1.4% · ROE 1.7% · GNPA — 68% evidence | 4.1/20 P/BV 1.79× · P/BV÷ROE 1.05 70% evidence | 12.1/20 RS sector 3.6% · RS bench 2.1% · 1Y 47.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 17.3 + 12.3 + 4.1 + 12.1 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jackson Financial Inc.JXN | 45.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 11.1/35 Income -20.5% · PAT -311.5% 45% evidence | 4.7/25 ROA -0.1% · ROE -4.1% · GNPA — 68% evidence | 9.8/20 P/BV 0.78× · P/BV÷ROE — 10% evidence | 20.0/20 RS sector 17.2% · RS bench 15.7% · 1Y 36%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 4.7 + 9.8 + 20 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11F&G Annuities & Life, Inc.FG | 43.7/100Mixed-negative evidence67% evidence | BASING | 24.0/35 Income 18.2% · PAT 7.1% 45% evidence | 9.7/25 ROA 0.3% · ROE 5.4% · GNPA — 68% evidence | 8.6/20 P/BV 0.73× · P/BV÷ROE 0.14 70% evidence | 1.4/20 RS sector -22.2% · RS bench -23.2% · 1Y -30.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 9.7 + 8.6 + 1.4 = 43.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -22.2% and the one-year return is -30.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12MetLife, Inc.MET | 42.7/100Mixed-negative evidence80% evidence | LEADER | 11.8/35 Income 8.8% · PAT -14.9% 81% evidence | 8.8/25 ROA 0.1% · ROE 2.8% · GNPA — 68% evidence | 3.8/20 P/BV 1.97× · P/BV÷ROE 0.7 70% evidence | 18.3/20 RS sector 12.5% · RS bench 11% · 1Y 22.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 8.8 + 3.8 + 18.3 = 42.7 · Decision use: Price leads the evidence: RS versus the benchmark is 11%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Genworth Financial, Inc.GNW | 38.5/100Mixed-negative evidence76% evidence | BREAKING OUT | 10.3/35 Income 1% · PAT 0.3% 71% evidence | 7.0/25 ROA 0.1% · ROE 0.8% · GNPA — 68% evidence | 5.5/20 P/BV 0.35× · P/BV÷ROE 0.44 70% evidence | 15.7/20 RS sector 6.6% · RS bench 5.2% · 1Y 11.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 7 + 5.5 + 15.7 = 38.5 · Decision use: Price leads the evidence: RS versus the benchmark is 5.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Security National Financial CorporationSNFCA | 38.0/100Mixed-negative evidence70% evidence | ASLEEP | 15.9/35 Income 1.8% · PAT 40% 71% evidence | 9.2/25 ROA 0.5% · ROE 1.8% · GNPA — 68% evidence | 7.6/20 P/BV 0.58× · P/BV÷ROE 0.32 70% evidence | 5.3/20 RS sector -5.7% · RS bench -7% · 1Y 2.6%0 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 9.2 + 7.6 + 5.3 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Brighthouse Financial, Inc.BHF | 25.3/100Thin evidence · provisional55% evidence | ASLEEP | 10.7/35 Income -16.1% · PAT -109.7% 45% evidence | 4.2/25 ROA -0.3% · ROE -14% · GNPA — 68% evidence | 9.8/20 P/BV 0.62× · P/BV÷ROE — 10% evidence | 0.6/20 RS sector -23.6% · RS bench -24.7% · 1Y -15.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 4.2 + 9.8 + 0.6 = 25.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Prudential plcPUK | 53.6/100Thin evidence · provisional50% evidence | BASING | 18.7/35 Income — · PAT — 8% evidence | 17.8/25 ROA 2.9% · ROE 15.4% · GNPA — 51% evidence | 13.2/20 P/BV 1.96× · P/BV÷ROE 0.13 70% evidence | 3.9/20 RS sector -13.7% · RS bench -14.8% · 1Y -3.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 17.8 + 13.2 + 3.9 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Citizens, Inc.CIA | 35.1/100Thin evidence · provisional47% evidence | ASLEEP | 18.2/35 Income 7% · PAT 88.9% 29% evidence | 10.1/25 ROA — · ROE 1% · GNPA — 34% evidence | 3.8/20 P/BV 1.06× · P/BV÷ROE 1.06 70% evidence | 3.0/20 RS sector -35.8% · RS bench -36.6% · 1Y -40.1%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.1 + 3.8 + 3 = 35.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Abacus Global Management, Inc.'s stock price today?
Abacus Global Management, Inc. trades at $9.2, +47.8% over the past year. The company is valued at $1.0 B. The stock sits at 61% of its 52-week range of $5–$12, +1.1% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. — as of 17 September 2026.
What were Abacus Global Management, Inc.'s latest quarterly results?
Abacus Global Management, Inc. reported total income of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Income rose 50.0% and profit rose 0.0% year on year. Earnings per share were $0.07. The net margin was 16.7%, 8.3 pp lower than a year earlier. — as of 17 September 2026.
What is Abacus Global Management, Inc.'s revenue?
Abacus Global Management, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +50.0% year on year. For the full FY25 fiscal year, revenue was $0.2 B (+118.2%). Over the last 3 years revenue compounded at 81.7% a year. — as of 17 September 2026.
What is Abacus Global Management, Inc.'s profit?
Abacus Global Management, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.0 B. The net margin ran 16.7% in the latest quarter. — as of 17 September 2026.
What is Abacus Global Management, Inc.'s market cap?
Abacus Global Management, Inc.'s market capitalisation is $1.0 B at a stock price of $9.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Abacus Global Management, Inc.'s P/BV ratio?
Abacus Global Management, Inc. trades at a P/BV of 2.1×, at the 56th percentile of its own 1-year range, against a long-run median of 2.0×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Abacus Global Management, Inc. pay a dividend?
Yes — Abacus Global Management, Inc. declared $0.20 per share for Dec 25 (1 quarter on file, too few for a trailing-twelve-month total). — as of 17 September 2026.
What is Abacus Global Management, Inc.'s dividend per share?
Abacus Global Management, Inc.'s most recently declared dividend is $0.20 per share for Dec 25. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
Is Abacus Global Management, Inc. overvalued?
On its own history, Abacus Global Management, Inc. looks mid-range: its P/BV of 2.1× sits at the 56th percentile of its 1-year range (long-run median 2.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Abacus Global Management, Inc. growing?
The picture is mixed for Abacus Global Management, Inc.: latest-quarter revenue +50.0% year on year, profit +0.0%, and the net margin −8.3 pp at 16.7%. The 3-year compound rates are 81.7% (revenue) and 10.1% (profit). The earnings engine currently reads: mixed — as of 17 September 2026.
How is Abacus Global Management, Inc. performing?
Abacus Global Management, Inc.'s latest readings are below. Its latest quarter's income rose 50.0% and profit rose 0.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Abacus Global Management, Inc. beating the market?
Not lately — on a trailing-13-week view Abacus Global Management, Inc. is currently behind the S&P 500 (2 weeks and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.2 years the stock moved +87% against the S&P 500's +21% — ahead of the index over the full window. — as of 17 September 2026.
Will Abacus Global Management, Inc.'s stock price go up?
This page publishes no price forecast for Abacus Global Management, Inc. What it measures instead: the stock price is $9.2. Its P/BV of 2.1× sits at the 56th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Abacus Global Management, Inc.?
Yes — short interest is 10.5% of Abacus Global Management, Inc.'s tradable float, about 8.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Where is Abacus Global Management, Inc. in its business cycle?
Abacus Global Management, Inc.'s FY25 net margin was 16.7%, against a 4-year band of −18.2%–75.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Abacus Global Management, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Abacus Global Management, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Abacus Global Management, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!